Skip to search formSkip to main contentSkip to account menu

168 HR Buprenorphine 0.015 MG/HR Transdermal System [BuTrans]

Known as: buprenorphine 15 ug in 1 h TRANSDERMAL PATCH, EXTENDED RELEASE [Butrans], 168 HR BuTrans 0.015 MG/HR Transdermal System, BuTrans 15 MCG/HR Weekly Transdermal Patch 
National Institutes of Health

Related topics

Related topics

6 relations
BuTransBuprenorphinePovidoneTransdermal System

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate‐to‐Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials
To evaluate the impact of buprenorphine (Butrans®) transdermal System (BTDS) treatment on sleep outcomes for patients with… 
2013
2013
Long-term maintenance of improvements in patient-reported functioning, quality-of-life, and pain outcomes for moderate-to-severe chronic pain patients receiving continuous treatment of Butrans…
2013
2013
Dosing of patients newly treated with Butrans® (buprenorphine transdermal system)
2012
2012
Butrans® (buprenorphine) Transdermal System and 7-day analgesic efficacy
2011
2011
The adverse event profile of Butrans™ (buprenorphine) transdermal system in patients ≥ 65 and < 65 years of age
2011
2011
Application site adverse events of Butrans™ (buprenorphine) transdermal system
2011
2011
Transdermal buprenorphine (Butrans) for chronic pain.
The FDA has approved the partial opioid agonist buprenorphine in a transdermal formulation (Butrans-Purdue) for treatment of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)